Clinical Trial Update: Efficacy, Safety, Tolerability and Pharmacokinetics of KAF156 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection [Phase 2]

View source ↗

Summary

Phase 2 study evaluating KAF156 (ganaplacide) in adults with acute, uncomplicated malaria showed efficacy, tolerability and pharmacokinetics data with acceptabl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malaria

Drugs mentioned

• KAF156 (ganaplacide)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Malaria | Phase 2 | Status: COMPLETED | Results posted: 2015-08-19